+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 70Years
All Genders
ID06687382

Phase IIa Study of MBK-01 Intestinal Microbiota Capsules to Reduce Recurring Diverticulitis Episodes and Find the Best Dose

Led by Mikrobiomik Healthcare Company S.L. · Updated on 2025-06-05

81

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research focuses on patients with recurrent diverticulitis, a condition marked by repeated episodes of inflammation in the colon that significantly affects quality of life through physical, psychological, and social symptoms. Traditional antibiotic treatments often fail to control the disease in many patients, leading to chronic and recurrent episodes, and an increased risk of complications. The study aims to evaluate a new treatment approach using MBK-01, an oral capsule containing lyophilized intestinal microbiota, to reduce the frequency of diverticulitis episodes and improve patient outcomes. Participants will be randomly assigned to one of three groups one receiving MBK-01 without a maintenance dose, another receiving MBK-01 with a maintenance dose three months after the initial treatment, and a control group receiving no intervention. Those in the MBK-01 groups will first undergo a three-day antibiotic pre-treatment followed by a two-day washout period before starting MBK-01 capsules. The treatment involves an initial dose of 4 capsules on the first day and a daily capsule for the next 16 days, with the maintenance group receiving an identical regimen three months later. The control group will receive usual care without preventive medication. Throughout one year of follow-up, participants will attend six clinic visits to monitor health and treatment effects. These visits include physical exams, lab tests, stool samples, and questionnaires assessing gastrointestinal quality of life and general health. Researchers will track episodes of diverticulitis, hospitalizations, surgeries, antibiotic use, and any adverse events. The study will assess the safety, tolerability, and optimal dosing of MBK-01 while observing its impact on patient-perceived health outcomes and the frequency of diverticulitis episodes.

CONDITIONS

Brief Title

Clinical Trial With MBK-01, Intestinal Microbiota Capsules, for the Treatment of Patients With Recurrent Diverticulitis

Research Team

O

Olaia Aurtenetxe

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here